Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-704-4040
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$41.37 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Harrow Health (NASDAQ:HROW) Frequently Asked Questions
What is Harrow Health's stock symbol?
Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
How were Harrow Health's earnings last quarter?
Harrow Health (NASDAQ:HROW) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.03. The company had revenue of $13.52 million for the quarter, compared to analysts' expectations of $12.55 million. Harrow Health had a return on equity of 50.32% and a net margin of 51.32%. View Harrow Health's Earnings History.
When is Harrow Health's next earnings date?
Has Harrow Health been receiving favorable news coverage?
News headlines about HROW stock have been trending positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Harrow Health earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Harrow Health.
Are investors shorting Harrow Health?
Harrow Health saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,004,800 shares, an increase of 6.3% from the June 30th total of 945,400 shares. Based on an average daily volume of 302,700 shares, the days-to-cover ratio is presently 3.3 days. Approximately 4.7% of the shares of the company are short sold. View Harrow Health's Current Options Chain.
Who are some of Harrow Health's key competitors?
Some companies that are related to Harrow Health include Advanz Pharma (CXRXF), Karuna Therapeutics (KRTX), Endo International (ENDP), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Aptorum Group (APM), Syros Pharmaceuticals (SYRS), Atreca (BCEL), Sinovac Biotech (SVA), Magenta Therapeutics (MGTA), Crinetics Pharmaceuticals (CRNX), Dermira (DERM), Urogen Pharma (URGN) and Basilea Pharmaceutica (BPMUF).
What other stocks do shareholders of Harrow Health own?
Who are Harrow Health's key executives?
Harrow Health's management team includes the folowing people:
- Mr. Mark L. Baum, Founder, CEO & Director (Age 46)
- Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 37)
- Mr. John P. Saharek, Chief Commercial Officer (Age 59)
- Mr. David Moufarrège, VP of Technology
- Mr. Pramod Sharma Ph.D., VP of Quality
Who are Harrow Health's major shareholders?
Harrow Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.64%), Vanguard Group Inc. (4.53%), Acadian Asset Management LLC (2.27%), Sio Capital Management LLC (1.91%), BlackRock Inc. (1.74%) and Cadence Capital Management LLC (1.16%). View Institutional Ownership Trends for Harrow Health.
Which major investors are selling Harrow Health stock?
HROW stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Sio Capital Management LLC, Institutional & Family Asset Management LLC, Alambic Investment Management L.P., Citadel Advisors LLC, Panagora Asset Management Inc. and Ardsley Advisory Partners LP. View Insider Buying and Selling for Harrow Health.
Which major investors are buying Harrow Health stock?
HROW stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Cadence Capital Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Wedge Capital Management L L P NC, Corrado Advisors LLC, Westside Investment Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Harrow Health.
How do I buy shares of Harrow Health?
Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Harrow Health's stock price today?
One share of HROW stock can currently be purchased for approximately $5.15.
How big of a company is Harrow Health?
Harrow Health has a market capitalization of $129.63 million and generates $41.37 million in revenue each year. The company earns $14.63 million in net income (profit) each year or $0.61 on an earnings per share basis. View Additional Information About Harrow Health.
What is Harrow Health's official website?
How can I contact Harrow Health?
Harrow Health's mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The company can be reached via phone at 858-704-4040 or via email at [email protected]
MarketBeat Community Rating for Harrow Health (NASDAQ HROW)
MarketBeat's community ratings are surveys of what our community members think about Harrow Health and other stocks. Vote "Outperform" if you believe HROW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HROW will underperform the S&P 500 over the long term. You may vote once every thirty days.
